Esperion Therapeutics (NASDAQ:ESPR) Rating Increased to Buy at Wall Street Zen

Key Points

• Esperion Therapeutics has been upgraded from a "hold" to a "buy" rating by Wall Street Zen, reflecting a positive shift in analyst sentiment.
• The stock currently has a consensus rating of "Moderate Buy" with an average price target of $7.00, despite a recent target price cut by Needham & Company to $4.00.
• Esperion reported a quarterly EPS of ($0.02), surpassing expectations, with revenues of $82.39 million, indicating strong performance despite historical losses.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a report released on Sunday.

ESPR has been the subject of several other research reports. HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research report on Tuesday, June 17th. Needham & Company LLC dropped their price objective on Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $7.00.

Esperion Therapeutics Stock Up 3.9%

Shares of ESPR stock traded up $0.08 on Friday, reaching $2.13. The company had a trading volume of 4,298,610 shares, compared to its average volume of 6,786,300. The stock has a market capitalization of $429.45 million, a PE ratio of -4.35 and a beta of 0.82. Esperion Therapeutics has a one year low of $0.69 and a one year high of $3.94. The business's 50-day moving average is $1.40 and its 200 day moving average is $1.33.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.15. The business had revenue of $82.39 million during the quarter, compared to analyst estimates of $62.55 million. Esperion Therapeutics had a negative net margin of 35.84% and a negative return on equity of 0.91%. On average, sell-side analysts forecast that Esperion Therapeutics will post -0.29 earnings per share for the current fiscal year.

Institutional Trading of Esperion Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company boosted its holdings in Esperion Therapeutics by 7.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 72,705 shares of the biopharmaceutical company's stock valued at $72,000 after acquiring an additional 4,979 shares during the period. Private Advisor Group LLC boosted its holdings in Esperion Therapeutics by 33.2% during the 1st quarter. Private Advisor Group LLC now owns 40,106 shares of the biopharmaceutical company's stock valued at $58,000 after acquiring an additional 10,000 shares during the period. Boomfish Wealth Group LLC boosted its holdings in Esperion Therapeutics by 29.5% during the 2nd quarter. Boomfish Wealth Group LLC now owns 45,306 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 10,309 shares during the period. Invesco Ltd. boosted its holdings in Esperion Therapeutics by 15.5% during the 4th quarter. Invesco Ltd. now owns 97,833 shares of the biopharmaceutical company's stock valued at $215,000 after acquiring an additional 13,101 shares during the period. Finally, Two Sigma Advisers LP boosted its holdings in Esperion Therapeutics by 0.4% during the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company's stock valued at $7,956,000 after acquiring an additional 16,100 shares during the period. Institutional investors own 47.39% of the company's stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.